Published in Viruses on June 16, 2014
Viral and Synthetic RNA Vector Technologies and Applications. Mol Ther (2016) 0.80
Alphaviruses in gene therapy. Viruses (2015) 0.79
Novel antigen delivery systems. World J Virol (2015) 0.78
CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes. Immunology (2015) 0.78
Development of a Real-Time Cell Analysing (RTCA) method as a fast and accurate screen for the selection of chikungunya virus replication inhibitors. Parasit Vectors (2015) 0.76
Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel) (2016) 0.75
Special Issue: Gene Therapy with Emphasis on RNA Interference. Viruses (2015) 0.75
Oncolytic Alphaviruses in Cancer Immunotherapy. Vaccines (Basel) (2017) 0.75
Vaccines against Botulism. Toxins (Basel) (2017) 0.75
The alphaviruses: gene expression, replication, and evolution. Microbiol Rev (1994) 16.68
A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology (N Y) (1991) 7.08
Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science (1989) 4.84
Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology (1997) 3.62
Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology (1998) 2.81
Re-emergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet (1996) 2.72
Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg (2000) 2.39
Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology (N Y) (1993) 2.20
Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine (2000) 1.95
In vitro synthesis of infectious venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology (1989) 1.93
Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. J Virol (2001) 1.93
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat Med (2002) 1.88
Cancer therapy using a self-replicating RNA vaccine. Nat Med (1999) 1.76
Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol (1997) 1.73
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest (2010) 1.71
Two-helper RNA system for production of recombinant Semliki forest virus particles. J Virol (1999) 1.69
Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine (2009) 1.65
DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol (1998) 1.57
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis (2011) 1.45
DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology (1998) 1.42
Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res (2008) 1.41
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res (2000) 1.35
Alphavirus vectors for gene expression and vaccines. Curr Opin Biotechnol (1999) 1.34
Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc Natl Acad Sci U S A (1999) 1.30
Self-replicating Semliki Forest virus RNA as recombinant vaccine. Vaccine (1994) 1.30
Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV infection. Virology (1995) 1.29
Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol (1998) 1.25
Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. Virology (2001) 1.19
Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chickens against lethal infection with Hong Kong-origin H5N1 viruses. Virology (2000) 1.19
Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther (2002) 1.17
In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res (2007) 1.16
Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small (2010) 1.16
Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res Hum Retroviruses (1997) 1.16
Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine (2004) 1.12
Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology (2002) 1.12
Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol (2013) 1.11
DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther (2001) 1.11
An outbreak of human Semliki Forest virus infections in Central African Republic. Am J Trop Med Hyg (1990) 1.11
Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res (2004) 1.10
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine (2009) 1.08
Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine (2000) 1.08
Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis (2001) 1.07
Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol (2010) 1.07
Immunization against MUC18/MCAM, a novel antigen that drives melanoma invasion and metastasis. Gene Ther (2006) 1.03
Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res (2001) 1.03
Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon, and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology (1999) 1.02
Characterization of immune responses elicited in macaques immunized sequentially with chimeric VEE/SIN alphavirus replicon particles expressing SIVGag and/or HIVEnv and with recombinant HIVgp140Env protein. AIDS Res Hum Retroviruses (2006) 1.01
Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J Infect Dis (2002) 1.01
Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther (2001) 1.00
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One (2010) 0.99
A chimeric alphavirus replicon particle vaccine expressing the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. J Virol (2010) 0.99
Outbreak of Chikungunya in the Republic of Congo and the global picture. J Infect Dev Ctries (2011) 0.99
Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol (2011) 0.98
Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol (1999) 0.97
An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine (2000) 0.97
Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine (2007) 0.97
Biology and application of alphaviruses in gene therapy. Gene Ther (2005) 0.96
Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther (2012) 0.96
Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus type 1 VP22 protein to antigen. J Virol (2001) 0.96
Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect Immun (2003) 0.95
Marburg virus vaccines: comparing classical and new approaches. Vaccine (2001) 0.95
Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis (2010) 0.94
A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res (2007) 0.93
Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett (2001) 0.92
Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus. J Immunol (2002) 0.92
Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines (2003) 0.92
Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum Gene Ther (2001) 0.91
Establishment of an HLA-A*0201 human papillomavirus type 16 tumor model to determine the efficacy of vaccination strategies in HLA-A*0201 transgenic mice. Cancer Res (2002) 0.91
Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. Antivir Ther (2004) 0.91
Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim Biophys Acta (2003) 0.90
Layered amplification of gene expression with a DNA gene delivery system. Ann N Y Acad Sci (1995) 0.90
RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun (2008) 0.89
Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg (2002) 0.89
Infected dendritic cells are sufficient to mediate the adjuvant activity generated by Venezuelan equine encephalitis virus replicon particles. Vaccine (2012) 0.88
Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther (1999) 0.88
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine (2012) 0.87
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther (2006) 0.87
Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg (2001) 0.86
Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther (2002) 0.86
Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Ther (2005) 0.85
Superior protection conferred by inactivated whole virus vaccine over subunit and DNA vaccines against salmonid alphavirus infection in Atlantic salmon (Salmo salar L.). Vaccine (2012) 0.85
Sindbis virus replicon particles encoding calreticulin linked to a tumor antigen generate long-term tumor-specific immunity. Cancer Gene Ther (2006) 0.84
In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J Virol (2010) 0.83
Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther (2001) 0.83
Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol (2000) 0.83
Immunogenicity and protective efficacy of a DNA vaccine against Venezuelan equine encephalitis virus aerosol challenge in nonhuman primates. Vaccine (2010) 0.83
A sindbis virus replicon-based DNA vaccine encoding the rabies virus glycoprotein elicits immune responses and complete protection in mice from lethal challenge. Vaccine (2008) 0.82
Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12. Vaccine (2008) 0.82
Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine (2001) 0.82
Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology (2009) 0.81
Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7. Gene Ther (2000) 0.81
Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res (2005) 0.81
Replicon particle vaccine protects swine against influenza. Comp Immunol Microbiol Infect Dis (2010) 0.81
Induction of neutralizing antibodies to Hendra and Nipah glycoproteins using a Venezuelan equine encephalitis virus in vivo expression system. Vaccine (2010) 0.81